Comment
|
Western blot analysis showed the presence of VEGFR2, but not VEGFR1 in the spinal cord organotypic cultures. VEGFR2 is specifically located in large neurons in the ventral horn of the spinal cord that were identified as motoneurons.
|
Formal Description Interaction-ID: 3322
|
|
Drugbank entries
|
Show/Hide entries for
KDR
|
Drugbank
DB00398
|
|
Drugbank
DB01268
|
|
Drugbank
DB04727
|
N-(4-{4-AMINO-6-[4-(METHYLOXY)PHENYL]FUR ...
|
Drugbank
DB06938
|
4-[[2-[[4-chloro-3-(trifluoromethyl)phen ...
|
Drugbank
DB07183
|
N-(4-phenoxyphenyl)-2-[(pyridin-4-ylmeth ...
|
Drugbank
DB07274
|
N-cyclopropyl-6-[(6,7-dimethoxyquinolin- ...
|
Drugbank
DB07326
|
6-chloro-N-pyrimidin-5-yl-3-{[3-(trifluo ...
|
Drugbank
DB07333
|
N-(CYCLOPROPYLMETHYL)-4-(METHYLOXY)-3-({ ...
|
Drugbank
DB07334
|
N-[5-(ETHYLSULFONYL)-2-METHOXYPHENYL]-5- ...
|
Drugbank
DB07514
|
3-(2-aminoquinazolin-6-yl)-1-(3,3-dimeth ...
|
Drugbank
DB07528
|
3-(2-aminoquinazolin-6-yl)-4-methyl-1-[3 ...
|
Drugbank
DB07537
|
N'-(6-aminopyridin-3-yl)-N-(2-cyclopenty ...
|
Drugbank
DB08042
|
N~4~-methyl-N~4~-(3-methyl-1H-indazol-6- ...
|
Drugbank
DB08519
|
N~4~-(3-methyl-1H-indazol-6-yl)-N~2~-(3, ...
|
Drugbank
DB04727
|
N-(4-{4-AMINO-6-[4-(METHYLOXY)PHENYL]FUR ...
|
|
|
Comment
|
VEGF protects motoneurons against chronic glutamate excitotoxicity.
VEGF significantly protected spinal cord motoneurons from excitotoxic death.
|
Formal Description Interaction-ID: 3324
|
in spinal cord motoneurons; exposed to THA (a glutamate transporter inhibitor) to induce chronic glutamate neurotoxicity
|
Drugbank entries
|
Show/Hide entries for
VEGFA
|
Drugbank
DB00112
|
|
Drugbank
DB01017
|
|
Drugbank
DB01120
|
|
Drugbank
DB01136
|
|
Drugbank
DB01270
|
|
Drugbank
DB03088
|
|
Drugbank
DB03754
|
Tris(Hydroxymethyl)Aminomethane
|
Drugbank
DB06779
|
|
Drugbank
DB01270
|
|
Drugbank
DB03088
|
|
Drugbank
DB03754
|
Tris(Hydroxymethyl)Aminomethane
|
|
|
Comment
|
VEGF protects motoneurons against chronic glutamate excitotoxicity.
VEGF significantly protected spinal cord motoneurons from excitotoxic death.
|
Formal Description Interaction-ID: 3325
|
in spinal cord motoneurons; exposed to THA (a glutamate transporter inhibitor) to induce chronic glutamate neurotoxicity
|
Drugbank entries
|
Show/Hide entries for
VEGFA
|
Drugbank
DB00112
|
|
Drugbank
DB01017
|
|
Drugbank
DB01120
|
|
Drugbank
DB01136
|
|
Drugbank
DB01270
|
|
Drugbank
DB03088
|
|
Drugbank
DB03754
|
Tris(Hydroxymethyl)Aminomethane
|
Drugbank
DB06779
|
|
Drugbank
DB01270
|
|
Drugbank
DB03088
|
|
Drugbank
DB03754
|
Tris(Hydroxymethyl)Aminomethane
|
|
|
Comment
|
VEGF stimulation induces an increase in the phosphorylation of both Akt and ERK, with a maximal activation of both kinases after 12 h of exposure.
|
Formal Description Interaction-ID: 3326
|
in spinal cord motoneurons
|
Drugbank entries
|
Show/Hide entries for
VEGFA
or
MAPK3
|
Drugbank
DB00112
|
|
Drugbank
DB01017
|
|
Drugbank
DB01120
|
|
Drugbank
DB01136
|
|
Drugbank
DB01270
|
|
Drugbank
DB03088
|
|
Drugbank
DB03754
|
Tris(Hydroxymethyl)Aminomethane
|
Drugbank
DB06779
|
|
Drugbank
DB01270
|
|
Drugbank
DB03088
|
|
Drugbank
DB03754
|
Tris(Hydroxymethyl)Aminomethane
|
Drugbank
DB00605
|
|
Drugbank
DB01169
|
|
Drugbank
DB02733
|
|
Drugbank
DB04604
|
|
Drugbank
DB02733
|
|
|
|
Comment
|
VEGF stimulation induces an increase in the phosphorylation of both Akt and ERK, with a maximal activation of both kinases after 12 h of exposure.
|
Formal Description Interaction-ID: 3327
|
increases_phosphorylation of
in spinal cord motoneurons
|
Drugbank entries
|
Show/Hide entries for
VEGFA
or
MAPK3
|
Drugbank
DB00112
|
|
Drugbank
DB01017
|
|
Drugbank
DB01120
|
|
Drugbank
DB01136
|
|
Drugbank
DB01270
|
|
Drugbank
DB03088
|
|
Drugbank
DB03754
|
Tris(Hydroxymethyl)Aminomethane
|
Drugbank
DB06779
|
|
Drugbank
DB01270
|
|
Drugbank
DB03088
|
|
Drugbank
DB03754
|
Tris(Hydroxymethyl)Aminomethane
|
Drugbank
DB00605
|
|
Drugbank
DB01169
|
|
Drugbank
DB02733
|
|
Drugbank
DB04604
|
|
Drugbank
DB02733
|
|
|
|
Comment
|
VEGF stimulation induces an increase in the phosphorylation of both Akt and ERK, with a maximal activation of both kinases after 12 h of exposure.
|
Formal Description Interaction-ID: 3328
|
in spinal cord motoneurons
|
Drugbank entries
|
Show/Hide entries for
VEGFA
or
MAPK1
|
Drugbank
DB00112
|
|
Drugbank
DB01017
|
|
Drugbank
DB01120
|
|
Drugbank
DB01136
|
|
Drugbank
DB01270
|
|
Drugbank
DB03088
|
|
Drugbank
DB03754
|
Tris(Hydroxymethyl)Aminomethane
|
Drugbank
DB06779
|
|
Drugbank
DB01270
|
|
Drugbank
DB03088
|
|
Drugbank
DB03754
|
Tris(Hydroxymethyl)Aminomethane
|
Drugbank
DB01064
|
|
Drugbank
DB01169
|
|
Drugbank
DB02116
|
|
Drugbank
DB02482
|
|
Drugbank
DB02733
|
|
Drugbank
DB04338
|
|
Drugbank
DB06877
|
N,N-DIMETHYL-4-(4-PHENYL-1H-PYRAZOL-3-YL ...
|
Drugbank
DB07010
|
N-BENZYL-4-[4-(3-CHLOROPHENYL)-1H-PYRAZO ...
|
Drugbank
DB07264
|
(S)-N-(1-(3-CHLORO-4-FLUOROPHENYL)-2-HYD ...
|
Drugbank
DB07788
|
(3R,5Z,8S,9S,11E)-8,9,16-TRIHYDROXY-14-M ...
|
Drugbank
DB07794
|
5-(2-PHENYLPYRAZOLO[1,5-A]PYRIDIN-3-YL)- ...
|
Drugbank
DB07905
|
(1aR,8S,13S,14S,15aR)-5,13,14-trihydroxy ...
|
Drugbank
DB08513
|
[4-({5-(AMINOCARBONYL)-4-[(3-METHYLPHENY ...
|
Drugbank
DB08521
|
4-[5-(4-FLUORO-PHENYL)-2-(4-METHANESULFI ...
|
Drugbank
DB02482
|
|
Drugbank
DB02733
|
|
|
|
Comment
|
VEGF stimulation induces an increase in the phosphorylation of both Akt and ERK, with a maximal activation of both kinases after 12 h of exposure.
|
Formal Description Interaction-ID: 3329
|
increases_phosphorylation of
in spinal cord motoneurons
|
Drugbank entries
|
Show/Hide entries for
VEGFA
or
MAPK1
|
Drugbank
DB00112
|
|
Drugbank
DB01017
|
|
Drugbank
DB01120
|
|
Drugbank
DB01136
|
|
Drugbank
DB01270
|
|
Drugbank
DB03088
|
|
Drugbank
DB03754
|
Tris(Hydroxymethyl)Aminomethane
|
Drugbank
DB06779
|
|
Drugbank
DB01270
|
|
Drugbank
DB03088
|
|
Drugbank
DB03754
|
Tris(Hydroxymethyl)Aminomethane
|
Drugbank
DB01064
|
|
Drugbank
DB01169
|
|
Drugbank
DB02116
|
|
Drugbank
DB02482
|
|
Drugbank
DB02733
|
|
Drugbank
DB04338
|
|
Drugbank
DB06877
|
N,N-DIMETHYL-4-(4-PHENYL-1H-PYRAZOL-3-YL ...
|
Drugbank
DB07010
|
N-BENZYL-4-[4-(3-CHLOROPHENYL)-1H-PYRAZO ...
|
Drugbank
DB07264
|
(S)-N-(1-(3-CHLORO-4-FLUOROPHENYL)-2-HYD ...
|
Drugbank
DB07788
|
(3R,5Z,8S,9S,11E)-8,9,16-TRIHYDROXY-14-M ...
|
Drugbank
DB07794
|
5-(2-PHENYLPYRAZOLO[1,5-A]PYRIDIN-3-YL)- ...
|
Drugbank
DB07905
|
(1aR,8S,13S,14S,15aR)-5,13,14-trihydroxy ...
|
Drugbank
DB08513
|
[4-({5-(AMINOCARBONYL)-4-[(3-METHYLPHENY ...
|
Drugbank
DB08521
|
4-[5-(4-FLUORO-PHENYL)-2-(4-METHANESULFI ...
|
Drugbank
DB02482
|
|
Drugbank
DB02733
|
|
|
|
Comment
|
VEGF stimulation induces an increase in the phosphorylation of both Akt and ERK, with a maximal activation of both kinases after 12 h of exposure.
|
Formal Description Interaction-ID: 3330
|
in spinal cord motoneurons
|
Drugbank entries
|
Show/Hide entries for
VEGFA
or
AKT1
|
Drugbank
DB00112
|
|
Drugbank
DB01017
|
|
Drugbank
DB01120
|
|
Drugbank
DB01136
|
|
Drugbank
DB01270
|
|
Drugbank
DB03088
|
|
Drugbank
DB03754
|
Tris(Hydroxymethyl)Aminomethane
|
Drugbank
DB06779
|
|
Drugbank
DB01270
|
|
Drugbank
DB03088
|
|
Drugbank
DB03754
|
Tris(Hydroxymethyl)Aminomethane
|
Drugbank
DB00171
|
|
Drugbank
DB01169
|
|
Drugbank
DB01863
|
Inositol 1,3,4,5-Tetrakisphosphate
|
Drugbank
DB07584
|
N-[2-(5-methyl-4H-1,2,4-triazol-3-yl)phe ...
|
Drugbank
DB07585
|
5-(5-chloro-7H-pyrrolo[2,3-d]pyrimidin-4 ...
|
Drugbank
DB00171
|
|
Drugbank
DB01863
|
Inositol 1,3,4,5-Tetrakisphosphate
|
|
|
Comment
|
VEGF stimulation induces an increase in the phosphorylation of both Akt and ERK, with a maximal activation of both kinases after 12 h of exposure.
|
Formal Description Interaction-ID: 3331
|
increases_phosphorylation of
in spinal cord motoneurons
|
Drugbank entries
|
Show/Hide entries for
VEGFA
or
AKT1
|
Drugbank
DB00112
|
|
Drugbank
DB01017
|
|
Drugbank
DB01120
|
|
Drugbank
DB01136
|
|
Drugbank
DB01270
|
|
Drugbank
DB03088
|
|
Drugbank
DB03754
|
Tris(Hydroxymethyl)Aminomethane
|
Drugbank
DB06779
|
|
Drugbank
DB01270
|
|
Drugbank
DB03088
|
|
Drugbank
DB03754
|
Tris(Hydroxymethyl)Aminomethane
|
Drugbank
DB00171
|
|
Drugbank
DB01169
|
|
Drugbank
DB01863
|
Inositol 1,3,4,5-Tetrakisphosphate
|
Drugbank
DB07584
|
N-[2-(5-methyl-4H-1,2,4-triazol-3-yl)phe ...
|
Drugbank
DB07585
|
5-(5-chloro-7H-pyrrolo[2,3-d]pyrimidin-4 ...
|
Drugbank
DB00171
|
|
Drugbank
DB01863
|
Inositol 1,3,4,5-Tetrakisphosphate
|
|
|
Comment
|
The phosphorylation of Akt and ERK stimulated by VEGF was abrogated in the presence of the PI3-K inhibitor, LY294002 or the MEK inhibitor, U0126, respectively; indicating that VEGF activates these kinases via PI3-K and MEK, respectively.
|
Formal Description Interaction-ID: 3332
|
in spinal cord motoneurons
|
Drugbank entries
|
Show/Hide entries for
VEGFA
|
Drugbank
DB00112
|
|
Drugbank
DB01017
|
|
Drugbank
DB01120
|
|
Drugbank
DB01136
|
|
Drugbank
DB01270
|
|
Drugbank
DB03088
|
|
Drugbank
DB03754
|
Tris(Hydroxymethyl)Aminomethane
|
Drugbank
DB06779
|
|
Drugbank
DB01270
|
|
Drugbank
DB03088
|
|
Drugbank
DB03754
|
Tris(Hydroxymethyl)Aminomethane
|
|
|
Comment
|
The phosphorylation of Akt and ERK stimulated by VEGF was abrogated in the presence of the PI3-K inhibitor, LY294002 or the MEK inhibitor, U0126, respectively; indicating that VEGF activates these kinases via PI3-K and MEK, respectively.
|
Formal Description Interaction-ID: 3333
|
in spinal cord motoneurons
|
Drugbank entries
|
Show/Hide entries for
VEGFA
|
Drugbank
DB00112
|
|
Drugbank
DB01017
|
|
Drugbank
DB01120
|
|
Drugbank
DB01136
|
|
Drugbank
DB01270
|
|
Drugbank
DB03088
|
|
Drugbank
DB03754
|
Tris(Hydroxymethyl)Aminomethane
|
Drugbank
DB06779
|
|
Drugbank
DB01270
|
|
Drugbank
DB03088
|
|
Drugbank
DB03754
|
Tris(Hydroxymethyl)Aminomethane
|
|
|
Comment
|
VEGF mediates neuroprotection against chronic glutamate-induced neurotoxicity and restores the levels of Bcl-2 and survivin via PI3-K/Akt. VEGF restores Bcl-2 levels after chronic glutamate excitotoxicty.
|
Formal Description Interaction-ID: 3334
|
in spinal cord motoneurons; exposed to THA (a glutamate transporter inhibitor) to induce chronic glutamate neurotoxicity
|
Drugbank entries
|
Show/Hide entries for
VEGFA
or
BCL2
|
Drugbank
DB00112
|
|
Drugbank
DB01017
|
|
Drugbank
DB01120
|
|
Drugbank
DB01136
|
|
Drugbank
DB01270
|
|
Drugbank
DB03088
|
|
Drugbank
DB03754
|
Tris(Hydroxymethyl)Aminomethane
|
Drugbank
DB06779
|
|
Drugbank
DB01270
|
|
Drugbank
DB03088
|
|
Drugbank
DB03754
|
Tris(Hydroxymethyl)Aminomethane
|
Drugbank
DB01229
|
|
Drugbank
DB01248
|
|
Drugbank
DB01367
|
|
Drugbank
DB01229
|
|
|
|
Comment
|
VEGF mediates neuroprotection against chronic glutamate-induced neurotoxicity and restores the levels of Bcl-2 and survivin via PI3-K/Akt. VEGF restores survivin levels after chronic glutamate excitotoxicty.
|
Formal Description Interaction-ID: 3335
|
in spinal cord neurons; exposed to THA (a glutamate transporter inhibitor) to induce chronic glutamate neurotoxicity
|
Drugbank entries
|
Show/Hide entries for
VEGFA
|
Drugbank
DB00112
|
|
Drugbank
DB01017
|
|
Drugbank
DB01120
|
|
Drugbank
DB01136
|
|
Drugbank
DB01270
|
|
Drugbank
DB03088
|
|
Drugbank
DB03754
|
Tris(Hydroxymethyl)Aminomethane
|
Drugbank
DB06779
|
|
Drugbank
DB01270
|
|
Drugbank
DB03088
|
|
Drugbank
DB03754
|
Tris(Hydroxymethyl)Aminomethane
|
|
|